This is the text extract for June Tender Notification, browse documents here.

---

30 June 2009

TENDER RESULTS

The PHARMAC Board (or Chief Executive under delegated authority) has resolved to accept tenders for Sole Subsidised Supply and Hospital Supply Status for some of the products listed in the Invitation to Tender dated 23 December 2008. Some of the pharmaceuticals that will be delisted when the period of sole supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts until such time as the pharmaceuticals are delisted and PHARMAC will continue to subsidise their pharmaceuticals accordingly. Product Notification Forms Please note that for all changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H) suppliers are required to notify PHARMAC and the Guild by 4pm 10th July 2009. More information and product notification forms can be downloaded from our website – www.pharmac.govt.nz/schedule.asp. 2007/08 Tender Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 21 December 2007.

The decisions were as follows:

Chemical Name Piperacillin Sodium with Tazobactum Sodium Zidovudine (AZT)

Line Item Inj 4 g with tazobactam sodium 500 mg Oral liq 10 mg per ml

2008/09 Tender Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule 1. Tenders awarded to listed pharmaceuticals where no other brand is listed – subsidy changes (where applicable) on 1 August 2009 and Sole Subsidised Supply commences on 1 November 2009.

The decisions were as follows:

Chemical Name Atenolol Atenolol Nevirapine Nevirapine

Presentation; Pack size and type Tab 50 mg; 500 tablets, bottle Tab 100 mg; 500 tablets, bottle Oral suspension 10 mg per ml; 240 ml, bottle Tab 200 mg; 60 tablets, blister

Current Subsidy $6.50 $11.30 $134.55 $319.80

New tender subsidy $6.18 $10.73 $134.55 $319.80

Sole supply brand (Supplier) Pacific Atenolol (Mylan) Pacific Atenolol (Mylan) Viramune (Boehringer Ingelheim) Viramune (Boehringer Ingelheim)

A289074 - qA12214

---

2. Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for tender winning brand at the tender subsidy will occur on 1 August 2009, reference pricing of non-tender winning brand will occur on 1 October 2009 and Sole Subsidised Supply commences on 1 January 2010.

The decisions were as follows:

Chemical Name Calamine Calamine

Presentation; Pack size and type Crm, aqueous, BP; 100 ml, pot Lotn BP, 2,000 ml, bottle

Current subsidy $3.02 $19.44

New tender subsidy $2.78 $16.70

Sole supply brand (Supplier) healthE (Jaychem) API (API Consumers)

Brands affected by reference pricing and delisting ABM (ABM) ABM (ABM)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule 3. Tenders awarded to listed pharmaceuticals where only the current brand is listed – price changes (where applicable) for hospital tender winning brands of the pharmaceuticals will occur in Section H of the Pharmaceutical Schedule on 1 August 2009; DV Limits and DV Pharmaceuticals will apply from 1 October 2009.

The decisions were as follows:

Chemical Name

Presentation; Pack size and type

Hospital Supply Brand (Supplier)

Pack Price

DV Limit

DV Pharmaceuticals Brand Name (Supplier) Anselol (Douglas) Apo-Atenolol (Apotex) Atehexal (Novartis) Global Atenolol (Apotex) Anselol (Douglas) Apo-Atenolol (Apotex) Atehexal (Novartis) Global Atenolol (Apotex) Hospira (Hospira) Pharmorubicin (Pfizer) Hospira (Hospira) Pharmorubicin (Pfizer) Hospira (Hospira) Pharmorubicin (Pfizer) Hospira (Hospira) Pharmorubicin (Pfizer) (B) (B)

Atenolol

Tab 50 mg; 500 tablets, bottle

Pacific Atenolol (Mylan)

$6.18

1%

Atenolol

Tab 100 mg; 500 tablets, bottle

Pacific Atenolol (Mylan)

$10.73

1%

Epirubicin * Epirubicin * Epirubicin * Epirubicin * Nevirapine Sodium hyaluronate Sodium hyaluronate

Inj 2 mg per ml, 5 ml; 1 injection, vial Inj 2 mg per ml, 25 ml; 1 injection, vial Inj 2 mg per ml, 50 ml; 1 injection, vial Inj 2 mg per ml, 100 ml; 1 injection, vial

Epirubicin Ebewe (InterPharma) Epirubicin Ebewe (InterPharma) Epirubicin Ebewe (InterPharma) Epirubicin Ebewe (InterPharma)

$25.00 $87.50 $155.00 $310.00

1% 1% 1% 1% 1% 1%

Oral suspension 10 mg per ml; 240 ml, Viramune (Boehringer $134.55 bottle Ingelheim) Ophthalmic inj 14 mg per ml; 1 injection, syringe Healon GV (Advanced Medical Optics) $50.00

Ophthalmic soln 10 mg per ml; 1 Healon (Advanced $35.00 1% Provisc (Mylan) injection, syringe Medical Optics) * Note the pricing of Epirubicin Ebewe in Section B of the Pharmaceutical Schedule for PCT and ECP preparations will be amended accordingly

4. Tenders awarded to pharmaceuticals where no brand is listed - listing of the hospital tender winning brand of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on 1 August 2009 and DV Limits and DV Pharmaceuticals will apply from 1 October 2009.

A289074 - qA12214

Page 2 of 3

---

The decisions were as follows:

Chemical Name

Presentation; Pack size and type Tab 200 mg; 60 tablets, blister

Hospital Supply Brand (Supplier) Viramune (Boehringer Ingelheim) API (API Consumer)

Pack Price $319.80

DV Limit 1%

DV Pharmaceuticals Brand Name (Supplier) (B) Dal (MidWest Pharmaceutics) Orion (Orion)

Nevirapine

Paraffin

Yellow soft; 10 g, tube

$1.04

1%

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 23 December 2008.

The decisions were as follows:

Chemical Name Aciclovir Aciclovir Calcium Carbonate with Aminoacetic Acid Calcium Gluconate Clomiphene Citrate Cocaine Epirubicin Epirubicin Epirubicin Levodopa with Benserazide Levodopa with Benserazide Levodopa with Benserazide Levodopa with Benserazide Levodopa with Benserazide Lisinopril Pyrantel Embonate Pyrantel Embonate Sodium Hyaluronate Sodium Hyaluronate Travoprost Vincristine Sulphate Vincristine Sulphate Vitamin B Complex (BPC, strong) Vitamins (BPC cap strength)

Line Item Inj 500 mg Inj 1,000 mg Tab 400-420 mg with aminoacetic acid 180 mg Inj 10%, 10 ml Tab 50 mg Soln 4%, 2 ml BP Inj 1 mg per ml, 5 ml Inj 2 mg per ml, 2 ml Inj 2 mg per ml, 10 ml Cap 100 mg with benserazide 25 mg Cap 200 mg with benserazide 50 mg Cap 50 mg with benserazide 12.5 mg Cap long-acting 100 mg with benserazide 25 mg Tab dispersible 50 mg with benserazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg Oral suspension Tab Inj 10 mg per ml, 0.35 ml; and inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.4 ml Inj 10 mg per ml, 0.5 ml; and inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.55 ml Eye drops 0.004% Inj 1 mg per ml, 1 ml Inj 1 mg per ml, 2 ml Tab Tab

For the remaining products on the Invitation to Tender dated 21 December 2007 and the Invitation to Tender dated 23 December 2008 where no announcement has been made, either a decision is still pending, or is provisional and subject to the product gaining market approval and having sufficient stock. We will keep you informed regarding any changes for the remaining tender products as further decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.

A289074 - qA12214 Page 3 of 3